Enabling Extraordinary Lives for Sickle Cell Disease Patients

learn more »

Transforming Treatment of Severe Blood Disorders

learn more »

A Commitment to Serving Patients and Their Families

learn more »

Innovative Science

Through its scientific foundation, Global Blood Therapeutics (GBT) is committed to transforming the treatment of severe blood disorders. 

GBT440 targets the underlying mechanism of red blood cell sickling, which provides the potential to treat SCD rather than only its associated symptoms.

more »

Spotlight on GBT440

GBT440 is an oral, once daily, direct-acting hemoglobin modifier for the chronic, prophylactic treatment of patients with sickle cell disease (SCD).

With the promise of restoring normal hemoglobin function, GBT440 may be capable of halting the progression of SCD.

more »